Rallybio has dosed the first subject in a trial of a potential treament for foetal and neonatal alloimmune thrombocytopaenia (FNAIT).

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

In addition to Hitler, the entire Nazi leadership, the scientists who designed so many weapons, even in a very short range of ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...